Integration of RWE in HTA –
Quality HTA is pleased to announce the article “Integration of Real-world Evidence from Different Data Sources in Health Technology Assessment“, written by Pooyeh Grail, Jason R. Guertin, Kelvin K.W. Chan, and Mina Tadrous, published by the Frontier Journal of Pharmacy & Pharmaceutical Sciences is available now.
This study aimed to explore the integration of RWE utilizing diverse sources of RWD in HTA processes, when, where, and how RWE can be effectively applied, and the potential challenges and barriers associated with using different data sources.
Real-world data sources
HTA agencies need to define quality standards, and champion the development of methodologies and standard frameworks, perhaps specific to each data category, to address the challenges and better use of RWE in HTA. RWE can be used for understanding the impact of health technologies, confirmation of RCT evidence to improve the certainty around the impact, understanding the long-term impact, and expanding the usage of health technologies in populations beyond those in trials. RWE has the potential to address knowledge gaps and decrease uncertainty regarding the costs and long-term impact of health technologies in real-world settings. Following the reassessment, only technologies that have truly improved health outcomes for the relevant population and offer good value for money in real-world conditions may receive public funding. Healthcare systems may need to define new reimbursement strategies or adapt current funding policies to accommodate the routine use of RWE across various categories in HTA processes.